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Abstract
Aim: Despite the potential benefits of e-health interventions for patients with psy-
chosis, the integration of these applications into the clinical workflow and analysis of
their long-term effects still face significant challenges. To address these issues, we
developed the ReMindCare app. This app aims to improve the treatment quality for
patients with psychosis. We chose to study the app in real world and pragmatic man-
ner to ensure results will be generalizable.
Methods: This is a naturalistic empirical study of patients in a first episode of psycho-
sis programme. The app was purpose-designed based on two previous studies, and it
offers the following assessments: (a) three daily questions regarding anxiety, sadness
and irritability; and (b) 18 weekly questions about medication adherence, medication
side effects, medication attitudes and prodromal symptoms. The app offers
preset alerts, reminders and the ability for patients to reach out to their clinicians.
Data captured by the app are linked to the electronic medical record of the patient.
Patients will use the app as part of their ongoing care for a maximum period of
5 years, and assessments will occur at baseline and at the end of the first, second and
fifth years of app use.
Results: Recruitment started in October 2018 and is still ongoing.
Conclusions: The ReMindCare app represents early real-world use of digital mental
health tools that offer direct integration into clinical care. High retention and compli-
ance rates are expected, and this will in turn lead to improved quality of assessments
and communication between patients and clinicians.
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1 | INTRODUCTION
Early intervention programs for first-episode psychosis are effective
evidence-based interventions that foster recovery, prevent disability
and reduce costs associated with illness in both the short and long
Abbreviations: App, application; e-health, electronic health; EMR, electronic medical record;
FEPP, first episode of psychosis program; SQ, satisfaction questionnaire.
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term (Arango et al., 2017). However, like all clinical programs, they face
implementation challenges. Specific challenges identified by the RAISE
study in the United States include workforce development, community
activation, fidelity and measurement of outcomes and patient involve-
ment (Dixon, 2017). In Spain, which has a non-contributory health sys-
tem financed through taxation and supported by public funding,
universal health coverage and free health care services result in a lack
of professionals, tools and financial support to properly deliver these
interventions (Arango et al., 2017). Thus, interventions that reduce the
number of consultations and hospital admissions, enhance interview
efficiency, increase the early detection of illness and enhance treatment
efficacy are highly encouraged (Arango et al., 2018; MSCBS, 2019).
Research on smartphone ownership among youth receiving early inter-
vention services suggests that, like the rest of the population, they
increasingly own these devices; a 2015 study suggested 81% owner-
ship (Lal et al., 2015), and more recent research studies suggested 85%
(Aref-Adib et al., 2016) to 86% (Bonet et al., 2018) ownership. Further-
more, many studies have found high percentages of interest (70%-80%)
in e-health interventions among these patients (Bonet et al., 2017; Firth
et al., 2016; Gitlow et al., 2017), with no differences related to demo-
graphic or clinical characteristics (Berry, Lobban, Emsley, & Bucci, 2016;
Bonet et al., 2018).
Thus, in this digital age, it is not surprising that those with psycho-
sis are already turning to the internet and their smartphones for infor-
mation about their illness, peer support and local treatment resources
(Aref-Adib et al., 2016; Torous & Keshavan, 2018), creating an opportu-
nity for community engagement by using early intervention programs.
Perhaps, the greatest potential for digital technology for early interven-
tion programs is achieving fidelity and measurement of outcomes
through automatically quantifying patients' treatment trajectory
through real data, captured via surveys and sensors delivered via
patients' phones. Numerous studies have shown the feasibility and
acceptability of remotely monitoring location via smartphones and how
such data can be used to predict risk and stratify patients with schizo-
phrenia (Barnett et al., 2018; Bucci et al., 2018; Wang et al., 2016). By
capturing and quantifying the lived experiences of those with psycho-
sis, digital technology can help early intervention programs measure
functional recovery metrics, such as employment, social support and
medication adherence, in addition to subjective metrics.
However, despite the potential of digital technology to augment
early intervention care, efforts to date have been largely composed of
brief feasibility studies rather than actual clinical integration projects.
Most interventions analysed have been implemented in periods rang-
ing from 1 to 78 weeks, with the majority only implemented for
4 weeks or less (Berry et al., 2016; Bonet et al., 2017). A second limi-
tation is the feasibility of translating these interventions into daily
clinical practice, which has not been properly tested, as many studies
were not designed to be implemented in the hospital or clinical
workflow (Lauckner & Whitten, 2016; Zanaboni et al., 2018). More-
over, some studies suggested that, to achieve full integration into clin-
ical practice, organizations also need to adapt their systems to these
technologies; otherwise, success of the interventions would be
harmed (Appelbaum & Wohl, 2000). A third limitation is the impact of
digital health interventions on clinicians' workload and clinical effi-
ciency remains understudied (Gitlow et al., 2017; Hoerbst &
Schweitzer, 2015; Zanaboni et al., 2018). Finally, it is also important
to consider patients' perspectives outside of clinical studies. Although
the majority of studies found high levels of acceptance among
patients in terms of participation in e-health interventions (Berry
et al., 2016; Bonet et al., 2018), some studies have indicated that
excessive e-health communications could be regarded as repetitive,
intrusive or irritating (Kannisto, Adams, Koivunen, Katajisto, &
Välimäki, 2015; Palmier-Claus et al., 2013) or could increase worries
about illness (Kannisto et al., 2015). Thus the pragmatic and real world
nature of our study offers broad generalizable knowledge that con-
siders not only how the app may impact care but also how it can be
implemented into care.
The potential of digital mental health for early course psychosis
stands in sharp juxtaposition to the limited real-world clinical evidence
for its impact, integration and acceptability among both patients and
clinicians. To address these issues and improve the quality of early
intervention programs in patients with a first episode of psychosis, we
have developed an application (app) called “ReMindCare.” The
ReMindCare app was created as a tool that could be integrated into
standard psychiatric care and treatment, filling the gap between
research and clinical practice.
2 | METHODS
2.1 | Study objectives
The main objective of this study is to address whether the introduc-
tion of the ReMindCare App into daily clinical practice improves the
quality of treatment for patients in a first episode of psychosis pro-
gramme (FEPP).
Specifically, the aims of the study are (1) to assess the effective-
ness of the ReMindCare app, in terms of improvement of adherence
to anti-psychotic medication, early detection of relapses and improve-
ment of communication with clinicians, vs treatment as usual in
patients with a psychotic disorder; (2) to analyse the use of the
ReMindCare app by the patients in terms of rates of adherence, com-
pliance, alerts generated and the total time using the app; and (3) to
assess the satisfaction of patients with using the app and the per-
ceived usability of the ReMindCare app.
2.2 | Study design
In the protocol, we describe the ReMindCare intervention as the first
prospective naturalistic and empirical study of an app for FEPP. This
app aims to improve the quality of the evaluation and treatment of
patients. At the time of submitting this article, ReMindCare had been
introduced as a clinical tool into daily psychiatric practice for more
than a year. However, enrolment of patients continues, and the first
analysis of the data will be conducted by March 2020.
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2.3 | Study setting
The ReMindCare app was systematically integrated into the daily
FEPP workflow at the Public Clinical Hospital of Valencia (Spain),
where it is currently being used. This FEPP is a free care service that
aims to enhance the quality of the early care of outpatients with a first
episode of psychosis, from the early phases of the illness through the
first five critical years of treatment (Arango et al., 2017).
Given the pragmatic and naturalistic nature of this study, no
remuneration or compensation is offered to patients participating in
the programme or using the app. Rather, the app is offered as an addi-
tional and free service to the patients in treatment at study sites.
2.4 | Participants
2.4.1 | Recruitment and enrolment
Every outpatient from the FEPP who meets the criteria for inclusion is
considered a potential user of the ReMindCare app. Once patients enrol
in the study, they are able to use the app for a maximum period of 5 years,
which is the time when they would be discharged from the FEPP.
All patients interested in using the app must sign an informed
consent form and must complete some baseline assessments before
their inclusion in the study.
2.4.2 | Eligibility criteria
To be considered for this study, patients must be accepted into the
FEPP at the Clinical Hospital of Valencia. Criteria for inclusion in the
FEPP are:
Diagnosis of psychotic disorder following DSM-5 (APA, 2013) criteria,
interview conducted by a licensed clinician.
Less than 5 years of illness duration.
Residence associated with the hospital area of correspondence (Area
5 of Valencia).
Age between 17 and 65 years old
Ownership of a smartphone with an internet connection that allows
the proper installation and functioning of the app.
Exclusion criteria include the following:
Inability to use and master a mobile device and the Internet.
Refusal to sign an informed consent form.
Spanish/English language fluency limiting ability to partake in clinical
conversations or to understand the app questionnaires.
2.4.3 | Discontinuation and withdrawal
A patient's participation in the study will be discontinued if:
The patient provides an explicit notification of not wishing to continue
using the app.
Lack of use the app for a period longer than 2 months after having
been contacted by the research group over that period of inactivity.
Discharged from the FEPP or if their consent is revoked.
Given the naturalistic nature of this study, in case of discontinuation
or withdrawal, patients will continue with the usual psychiatric treat-
ment at the hospital.
2.5 | Intervention
2.5.1 | Application development
The development process for the ReMindCare app can be divided into
different phases, including review of the literature, a survey study, a
design phase, a pilot study phase and a final version phase.
We first conducted a systematic review of previous publications
on apps for psychosis (Bonet et al., 2017). Although the results of
this review suggested that apps are feasible and well accepted by
patients with psychosis, and apps can capture symptoms with good
correlation to traditional metrics, a lack of clinical integration was
notable across nearly all studies. Thus, to better understand how to
design an app optimized for clinical integration, we next conducted a
survey study of patient interests and preferences. We designed a
survey based on previous publications (Borzekowski et al., 2009;
Gay, Torous, Joseph, Pandya, & Duckworth, 2016; INE, 2016; Miller,
Stewart, Schrimsher, Peeples, & Buckley, 2015; NAMI, 2014;
Robotham, Satkunanathan, Doughty, & Wykes, 2016; Trefflich,
Kalckreuth, Mergl, & Rummel-Kluge, 2015) and administered it to a
sample of 113 patients with psychosis. We aimed to evaluate the
actual feasibility of e-health interventions in a potential sample of
patients with psychosis in our target population and to evaluate the
interest of these patients in e-health interventions (Bonet
et al., 2018). The results highlighted that apps must offer improved
communication with clinicians.
Next, we codesigned an e-health app called ReMindCare with a
team of clinicians, patients and developers. Our main objective of this
process was to ensure the usability of the app. In this regard, both the
patients and prior work in this space led us to focus on displaying
information in the app graphically to easily allow a quick overview of
the results and analysis of relevant information. We used a set of
information technologies that simplified the development and com-
munication between different parts of the platform. This included uti-
lizing free and open source software tools such as the MongoDB
database (MongoDB, GNU AGPL v3.0) to ensure flexibility and scal-
ability, a Node.js server (Node.js, MIT Licence) to power the app,
Docker containers (Docker, Apache Licence 2.0.) to protect privacy
and frameworks such as Meteor and Bootstrap to build responsive
user interfaces. This development of the app was conducted in a test
environment outside the hospital network. Early efforts in this phase
were focused on proper functioning of the database, the website and
the mobile application.
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With a functional first version of the ReMindCare app, we next
focused on the challenges related to integration of the app into the
hospital system. First, we had to study the current digital infrastruc-
ture of the hospital and adapt the platform to achieve its integration
into the system while ensuring the performance of the app remained
as designed, and patient data privacy was maintained. User authenti-
cation around the identification of both physicians and patients was a
barrier that we faced. This identification was carried out through the
F IGURE 1 Screen shot of the ReMindCare dashboard (App for patients). Example of daily evaluation questions
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Lightweight Directory Access Protocol (LDAP), which allows access to
an organized and distributed directory service for an information sea-
rch. The identification of patients and the report uploading was real-
ized using Health Level Seven (HL7), which is an international set of
standards to facilitate the electronic exchange of clinical information.
This development process and installation of the app took approxi-
mately 2 years, with the most time spent on the clinical integration of
the app into the hospital electronic system.
Although the process of integration was underway, we conducted
a pilot study to test the validity and usability of the platform. This pilot
trial involved four patients with psychosis for a period of 3 months,
during which no negative effects associated with app use were found.
The rates of compliance to surveys within the app were between 90%
and 97%. Based on user feedback, we conducted further modifica-
tions to ensure the accurate functioning of the app in regards clini-
cians access to the app website, privacy of data registration and
technical and electronic adjustments to achieve the automatic syn-
chronization of ReMindCare with Android updates to ensure the
appropriate performance of the app among different Android versions
and smartphones.
2.5.2 | ReMindCare app
ReMindCare is a free and user-friendly app that conducts daily evalua-
tions of the health status of patients with psychosis by offering quick
questionnaires. Two types of questionnaires are presented (Figure 1):
• Daily questionnaires: Three daily questions that assess levels of anx-
iety, sadness and irritability.
• Weekly questionnaires: Eighteen weekly questions aimed to assess
adherence to medication (1), the presence of side-effects to anti-
psychotic medication intake (5), the attitude towards medication
intake (3) and the presence of prodromal psychosis symptoms (9).
To use this clinical tool, clinicians enrol their patients via a private
portal. Once the patients are registered into the portal, they can
F IGURE 2 Screen shot of the ReMindCare dashboard (Website
for clinicians). List of questions presented to patients
F IGURE 3 Screen shot of the ReMindCare Dashboard (for
clinicians). Example of daily evaluation graphics
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download the app, which is available on “Google Play,” log into the
app and begin to use it. Patients are instructed on how to download
and log into the app, and they are informed regarding how their app
data are used.
The information gathered by the app is accessible to clinicians on
the portal, and it is exclusively used to orient clinicians for upcoming
visits with patients, to help both patients and clinicians have a shared
vision of the status of the patient and to discuss and establish
together the therapeutic approaches. In addition, as displayed in Fig-
ures 2 and 3, on this portal, clinicians can not only visualize the
information but also generate a PDF report that summarizes this
information. These reports can be uploaded to the electronic medical
record (EMR) of the patient because we enabled a function in the
electronic hospital system that allows the inclusion of the
ReMindCare app reports as another type of clinical report (eg, similar
to results from a blood pressure test or glucose test). Moreover, if
patients do not respond to notifications or abrupt variation in their
answers occurs, the system automatically generates “alarms or warn-
ings.” These alarms notify the clinician by e-mail and are also displayed
in the profile of the patient on the website. Moreover, patients are











Clinical Global Impression Scale (CGI) (Busner &
Targum, 2007)
X X X
Global Assessment of Functioning (GAF) (Endicott,
Spitzer, Fleiss, & Cohen, 1976)
X X X
Positive and Negative Syndrome Scale (PANSS)
(Peralta & Cuesta, 1994)
X X X
Premorbid Adjustment Scale (PAS) (Cannon-Spoor,
Potkin, & Wyatt, 1982)
X X X
Drug Attitude Inventory (DAI-10) (Hogan, Awad, &
Eastwood, 1983)
X X X
Beck Cognitive Insight Scale (BCIS)
(Beck, Baruch, Balter, Steer, & Warman, 2004)
X X X
Sociodemographic information (Age, sex, ethnicity,




(Diagnose, years of illness, pharmacological
treatment, suicidal attempts, history of illness)
X X X X
Outcome measures
Simplified Medication Adherence Questionnaire
(SMAQ) (Morisky, Green, & Levine, 1986)
X X X X
Number of relapses X X X X
Number of visits to urgent care units at the hospital X X X X
Number of hospital admissions X X X X
ReMindCare measures
Answers to questionnaires X X X X
Quantity of “urgent consultation” requests X X X X
Quantity of alarms generated X X X X
Satisfaction Questionnaire† X X
Note: t1 = introduction of the ReMindCare app into clinical practice; t2 = first-year preliminary data assessment; t3 = focus group, first year; t4 = second-
year follow-up; t5-8 = fifth-year follow-up; Satisfaction questionnaire
† = App feedback questionnaire made for the purpose of this research.
6 BONET ET AL.
able to contact their clinician using an “Urgent Consultation” tab dis-
played on the app if they detect a significant worsening in their health
status. By clicking this button, clinicians receive a notification e-mail
and have to contact the patient within a maximum period of 48 hours.
Further information about the use of the app and the webpage is
available in the user manual included in Appendix A.
2.6 | Data collection and measures
An overview of all included measures and assessment points is
included in Table 1.
Baseline surveys, including clinical and sociodemographic infor-
mation and clinical standardized questionnaires, were administered
before the enrolment of the patient in the study. As shown in Table 1,
data regarding the main outcomes, such as adherence to medication,
number of relapses, number of visits to the hospital urgent care units
and number of hospital admissions, will be collected and analysed at
the end of the first, second and fifth years of the intervention. More-
over, information generated for patients through the use of the app
will also be analysed at the same timepoints. Finally, to analyse the
feedback of patients regarding the use of the app, we plan to conduct
focus groups at the end of the first year of the intervention, and we
have also designed a “satisfaction questionnaire” (SQ) that patients
will complete at the end of the first year of the intervention or before
discontinuing the use of the app (if discontinuation occurs before the
first year of app usage). This SQ was made for the purpose of this
research study and is based on previous satisfaction and usability
questionnaires, such as the user version of the Mobile Application
Rating Scale (uMARS) (Stoyanov, Hides, Kavanagh, & Wilson, 2016),
the System Usability Scale (SUS) (Brooke, 1996), EnLight: a tool for
mobile and web-based eHealth interventions (Baumel, Faber, Mathur,
Kane, & Muench, 2017) and the App Quality Evaluation (AQEL)
(DiFilippo, Huang, & Chapman-Novakofski, 2017). This questionnaire
is displayed in Appendix B.
2.7 | Planned data analysis
Descriptive analyses of sociodemographic and clinical variables will
be conducted. A multivariate data analysis will be carried out to
explore relationships between sociodemographic and clinical vari-
ables and adherence to treatment and ReMindCare measures. An
ANOVA model of repeated measures will be used for the main
research outcomes. All analyses will be conducted with an alpha set
at P < 0.05.
These preliminary quantitative data analyses and the preliminary
results regarding patient compliance, retention rate and perceived sat-
isfaction with the use of the ReMindCare app are expected by the
end of the first year of using the app (March 2020). At that time, qual-
itative analyses of data are also planned.
Subsequent analysis of the data will be conducted at the end of
the second and fifth years of use of the app.
2.8 | Ethics, data privacy and participant safety
The ReMindCare app project has received full approval from the
Research Ethics Committee of the faculty of Medicine at the Univer-
sity of Valencia and from the Research Ethics Committee of the Sani-
tary Research Institute (INCLIVA) of the Clinical Hospital of Valencia,
Spain.
To protect the data sent by patients, communications to the
platform are encrypted with a transport layer security certificate
from the Generalitat Valenciana and are sent through the HTTPS
(Hypertext Transfer Protocol Secure) protocol. This process ensures
that all transmitted data are completely private and without a
chance of being manipulated. Moreover, the hospital infrastructure
is protected through a reverse proxy, which enhances security by
establishing a single access point to it and hiding all inner infra-
structures. Moreover, the integration of the app into the hospital
systems is subjected to the LOPD-GDD (Organic Law 3/2018: pro-
tection of personal data and digital rights guarantee, December
5th), the Spanish organic law adaptation of the GDPR (General
Data Protection Regulation).
3 | RESULTS
The ReMindCare app was systematically introduced into clinical prac-
tice in October 2018, and 57 patients have been enrolled in the study
since then. Updates of the app and improvements in its functioning
will be conducted as requested by feedback obtained from patients
and clinicians and in accordance with Android and iOS developments.
4 | DISCUSSION
ReMindCare is an e-health intervention aimed at improving the qual-
ity of the current programme for early treatment of patients with psy-
chosis. Although there are an increasing amount of apps being studied
for early course psychosis (Camacho, Levin, & Torous, 2019), to our
knowledge, this is the first pragmatic and prospective integration of
an app into real world clinical care. The study is thus designed to gen-
erate data beyond just how the app may improve care but also how it
can be implemented into clinical care, leading to the ability to aug-
ment quality existing health services (Bonet et al., 2017).
4.1 | Anticipated results
On the basis of previous studies (Bonet et al., 2017; Firth et al., 2016;
Gitlow et al., 2017) that confirmed the interest of patients with psy-
chosis in e-health interventions and based on the high interest in
owning an e-health app that we found in our survey study (Bonet
et al., 2018), we expect an acceptable retention rate (beyond 70%).
Moreover, based on previous studies (Ben-Zeev et al., 2014; Ben-
Zeev, Kaiser, & Krzos, 2014; Brenner & Ben-Zeev, 2014; Kimhy,
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Vakhrusheva, Liu, & Wang, 2014; Macias et al., 2015) that found rates
of response to the communications of e-health apps to be higher than
70%, we also expect moderate compliance with the app's communica-
tions (beyond 70%).
Furthermore, as previous studies have stated that electronic
assessments are valid and reliable measures (Brenner & Ben-Zeev,
2014; Kimhy et al., 2014; Palmier-Claus et al., 2013; Spaniel
et al., 2008), and based on preliminary perceptions obtained from the
first 7 months of the current intervention, we expect that the use of
the ReMindCare app would produce the following differences in the
treatment of psychotic disorders:
• Improved quality of treatment delivery for clinicians: Graphics of daily
and weekly questionnaires allow clinicians to rapidly assess the sta-
tus of the patient and to specifically orient their interactions with
the patient to problematic areas. An improvement in the quality of
evaluation is also expected. Perceptions of the clinicians regarding
these issues will be qualitatively assessed in focus groups.
• Improved insight about the illness and mental health status for
patients: Sharing with patients their responses to the app is
expected to increase accuracy of information and to decrease bias
in this process. Moreover, it is expected that, by discussing their
app responses with the patients, insight about their illness and
their health status will increase. These perceptions will be mainly
assessed by the “satisfaction questionnaire” (SQ), and they will also
be assessed qualitatively in focus groups. Moreover, changes in
insight between baseline and 1 year of intervention will be
assessed by using the BCIS (Beck et al., 2004).
• Improved quality of communication between patient and clinician: It
is expected that patients will feel more understood as a result of
improvements in evaluation and quality of their interactions with
the clinician, which could lead to an enhancement of the overall
quality of communication and alliance between patient and clini-
cian. Again, this will be assessed by the SQ and the focus groups.
• Improved adherence to treatment for patients: As a result of
improvements in insight about the illness and improvements in
alliance with clinicians, an enhancement of adherence to treat-
ment is also anticipated. Significant differences are expected in
the SMAQ (Hogan et al., 1983) scores of patients between base-
line and 1 year of intervention. Moreover, the number of relapses,
treatment dropouts and rates of compliance and adherence to
ReMindCare tests will also be analysed in this regard. It is
expected that the more patients use ReMindCare (high rates of
engagement and compliance), the fewer treatment dropouts and
relapses there will be.
• Improved early relapse detection and hospital admission reduction:
Again, higher rates of engagement with ReMindCare are expected
to produce lower hospital admissions, early detection of relapses
and fewer visits to urgent care units. Moreover, rates of relapses,
changes in medication and visits to urgent care units will be com-
pared among patients who used the “urgent consultation” function
and those who do not. We expect that using this function will
improve the quality of early detection.
• Improved quality of communication between health care providers
and improved quality of treatment decisions: Due to general access
of health care professionals to ReMindCare reports on the EMR,
we expect improved communication between health professionals
and, because of this, improved quality of treatment. Perceptions of
clinicians on this issue will be qualitatively assessed in focus
groups.
4.2 | Strengths and limitations
The main strength of our approach is the simplicity of the app and the
direct integration of ReMindCare into daily clinical practice. As stated
before, one of the most important factors regarding the sustainability
of e-health interventions relies upon good integration into the
workflow of health systems (Abbott, Foster, Marin Hde, &
Dykes, 2014; Appelbaum & Wohl, 2000; Cresswell & Sheikh, 2013;
Granja, Janssen, & Johansen, 2018). The ReMindCare app was
designed with the main objective of being useful not only for patients
but also for health providers. In this regard, the user-friendly design of
the app, its integration into the public hospital workflow and the free
access to the app for patients are major strengths that aim to ensure
the use of the app by both patients and clinicians and to improve, as a
result, the quality of treatment that patients receive and the quality of
health services that clinicians provide.
Another main strength of our study is that the development of
the app was based on two previous studies (Bonet et al., 2017, 2018),
which allowed us to be confident about the theoretical framework of
the intervention and to truly address the necessities of the patients.
As we found in our study (Bonet et al., 2018), patients claimed
improvements in communication with clinicians, which was one of our
main objectives when we designed the app.
The graphical display of information can be regarded as another
major strength. The integrated graphics provide a quick overview of
the health status of the patient, which is extremely useful in the con-
text of a busy public health system (Arango et al., 2018). Specifically,
these graphics can help clinicians detect side-effects of medication
that are not usually commented on by patients, such as sexual dys-
functions. This is relevant, as medication side-effects are one of the
most important factors affecting medication dropouts (García
et al., 2016).
Finally, the ReMindCare app has been developed in three lan-
guages, Spanish, English and Catalan, which allows the use of the app
in different countries and autonomous communities.
However, some limitations must be taken into consideration. First,
because of the characteristics of this real-world intervention, our study
is not randomized or controlled. However, we plan to compare the
main outcomes of the use of the app between users and age-matched
controls, although the groups may differ in some characteristics.
Another limitation is that ReMindCare has only been designed for
Android systems, although an iOS version of the app is being designed.
To our knowledge, this is one of the earliest e-health interven-
tions for patients with psychosis implemented as a standard care tool
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integrated into clinical practice in the public hospital workflow. Real-
time health information is being collected and used to work together
with patients to improve the quality of real-world health care delivery.
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